Interferon-gamma(-/-) (IFN-gamma(-/-)) and IFN-gamma(+/+) C57BL/6 mice (3 weeks of age) completed the production of morphogenesis-derived hair. Around 6 weeks of age, however, most of the IFN-gamma(-/-) but none of the IFN-gamma(+/+) mice began to lose hairs in the dorsal and occipital areas in the absence of inflammatory reactions, and the alopecia was sustained for at least several 10-week periods of observation. A single subcutaneous injection of IFN-gamma to IFN-gamma(-/-) mice at 3, but not 4, 5, or 8 weeks of age could protect all the mice from alopecia, revealing that the lack of IFN-gamma around 3 weeks of age is directly responsible for the alopecia. Histologic features showed that the hair follicles of the IFN-gamma(+/+) mice passed through the anagen (4-5 weeks of age) and catagen/telogen ( approximately 6 weeks of age) phases, whereas those of IFN-gamma(-/-) mice (5 weeks of age or older) stayed in the anagen phase. TUNEL and bromodeoxyuridine experiments suggested that an arrest with unlimited DNA synthesis of the hair cycle in the anagen phase by the lack of IFN-gamma-dependent apoptosis in the midfollicle region and diffuse shedding of previously formed hair induced alopecia in IFN-gamma(-/-) mice.

Download full-text PDF

Source
http://dx.doi.org/10.1089/10799900260286641DOI Listing

Publication Analysis

Top Keywords

weeks age
28
hair cycle
12
anagen phase
12
mice weeks
12
ifn-gamma-/- mice
12
cycle anagen
8
ifn-gamma-/- ifn-gamma+/+
8
ifn-gamma+/+ mice
8
mice
7
weeks
7

Similar Publications

Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.

Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.

View Article and Find Full Text PDF

Background: Ruptures of the distal biceps tendon (DBT) can affect the range of motion and strength of the elbow, raising concerns for patients seeking to restore normal function and engage in their regular activities, particularly returning to previous levels of sport participation.

Purpose: To characterize and assess the rate and timing of return to sport (RTS) after DBT repair.

Study Design: Systematic review; Level of evidence, 4.

View Article and Find Full Text PDF

Onabotulinum Toxin A-Led Urinary Tract Infections-Should we Safeguard? A Randomized Controlled Trial.

Int Urogynecol J

January 2025

Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA.

Introduction And Hypothesis: The objective of our study was to evaluate the need for antibiotic prophylaxis for urinary tract infection (UTI) prevention before Onabotulinum toxin A injection for overactive bladder (OAB). We hypothesize that the lack of antibiotic prophylaxis might not be inferior to administering prophylaxis.

Methods: This was a multi-centered, nonblinded, randomized controlled trial conducted between August 2022 and September 2024.

View Article and Find Full Text PDF

Intrahepatic portosystemic shunt: salvage mechanism for oligohydramnios complicating fetal growth restriction.

Ultrasound Obstet Gynecol

January 2025

Ultrasound Unit, Helen Schneider Hospital for Women, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.

Objective: Portosystemic shunts in growth-restricted fetuses are more common than previously thought. We aimed to describe fetuses with growth restriction and transient oligohydramnios in which a congenital intrahepatic portosystemic shunt (CIPSS) was noted during follow-up.

Methods: This was a retrospective study of all fetuses diagnosed with growth restriction and transient oligohydramnios during a 5-year period in a large tertiary referral center.

View Article and Find Full Text PDF

Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI.

Radiology

January 2025

From the Department of Radiology, Thomas Jefferson University Hospital, 132 S 10th St, 763G Main Bldg, Philadelphia, PA 19107 (A.L., C.K.Y.E., T.S.X., S.K.R., C.E.W., K.B., J.R.E., F.F.); Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (F.P.); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (F.P.); University of California San Diego, San Diego, Calif (Y.K.); University of Calgary, Calgary, Canada (A.M.K., S.R.W.); Einstein Medical Center, Philadelphia, Pa (S.K.R.); Vanderbilt University, Nashville, Tenn (V.P.); Stanford University, Stanford, Calif (A.K.); UT Southwestern Medical Center, Dallas, Tex (D.T.F.); Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland (A.B., I.P.R.); Department of Imaging Sciences, School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom (P.S.S.); and Department of Radiology, King's College Hospital, London, United Kingdom (P.S.S.).

Background Indeterminate focal liver observations in patients at risk for hepatocellular carcinoma (HCC) may require invasive biopsy or follow-up, which could lead to delays in definitive categorization and to postponement of treatment. Purpose To examine clinical effect of contrast-enhanced US (CEUS) in participants with high-risk indeterminate liver observations categorized as Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) or LI-RADS category LR-M (probably or definitely malignant but not HCC specific) at CT or MRI. Materials and Methods This was a secondary analysis of a prospective international multicenter validation study for CEUS LI-RADS (January 2018 to August 2021).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!